Loading
uniQure N.V. Stock: price and insider trades · United States
uniQure N.V.: what insiders have been doing
uniQure N.V. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 19 insiders have disclosed 60 filings since 19 October 2025.
The flow runs one way only: 21 sales worth €2.7M, from 5 insiders, and no purchase. The totals do not cover 10 filings with an undisclosed amount. Abi-Saab Walid filed the largest sale, €535k, on 12 May 2026, which represents 0.019% of the company's market value.
With 60 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Since 2021, the database holds no purchases and 100 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 16.1 m USD and net income of -199.0 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Vivos Inc and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
226
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€7M
100 ops. · all time
Who traded when
BuySaleMatthew C. Kapusta8 sales
Walid Abi-Saab7 sales
Madhavan Balachandran6 sales
Klemt Christian3 sales
Potts Jeannette2 sales
Gut Robert1 sale
+5 other insiders
Analyst consensus: bullish or bearish?
Analysts rate uniQure N.V. Strong Buy (bullish), based on 12 analysts. Average price target: US$61.43.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,743 of 26,279 companies
31.6
score / 100
Value15
Quality48
FCF yld-11%
Earn yld-13%
EV/EBITDA·
ROE-158%
Gross mgn90%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$21.78
Analyst consensus
12 analystsStrong buy
US$28.08Target US$61.43(+182%)US$91.83
Income statement
RevenueUS$16.1M
Gross profitUS$14.4M90% margin
EBITDA-US$116.6M-724% margin
Net income-US$199M-1236.0% margin
Valuation
PER (forward)-8.2x
P/Book4.7x
Beta1.06
Balance sheet & cash
Market capUS$1.5B
Total debtUS$63.4M
Free Cash Flow-US$178.4M
Debt / Equity170%
Profitability & ownership
ROE-157.6%
ROA-15.7%
% insiders1.3%
% institutions98.1%
Last declaration on 7 July 2026
Declarations226 total
9,200 shares@ US$44.430.015% mcap2.9% of flowOrdinary SharesSEC:0000904454-26-000397:1
4,282 shares@ US$45.430.0073% mcap1.4% of flowOrdinary SharesSEC:0000904454-26-000397:2
7,600 shares@ US$45.890.013% mcap2.5% of flowOrdinary SharesSEC:0000904454-26-000397:3
21,082 shares@ US$19.390.015% mcap2.9% of flowOrdinary SharesSEC:0000904454-26-000397:0
21,082 shares@ US$45.15380.036% mcap6.8% of flowORDINARY SHARESSEC144:0001973379-26-000264
10,000 sharesOrdinary SharesSEC:0000904454-26-000394:0
10,000 sharesOrdinary SharesSEC:0000904454-26-000394:1
20,000 sharesOrdinary SharesSEC:0000904454-26-000394:2
30,000 shares@ US$46.42140.052% mcap94.3% of flowOrdinary SharesSEC144:0001973379-26-000261
1,434 sharesOrdinary SharesSEC:0000904454-26-000387:0
1,434 shares@ US$46.85990.0023% mcap4.6% of flowOrdinary SharesSEC144:0001973379-26-000259
4,128 sharesOrdinary SharesSEC:0000904454-26-000375:0
6,696 sharesOrdinary SharesSEC:0000904454-26-000375:1
28,716 sharesOrdinary SharesSEC:0000904454-26-000375:2
28,716 sharesOrdinary SharesSEC:0000904454-26-000375:3
28,716 shares@ US$50.01760.049% mcap10.3% of flowORDINARY SHARESSEC144:0001973379-26-000254
6,696 shares@ US$50.000.011% mcap2.4% of flowORDINARY SHARESSEC144:0001973379-26-000252
6,390 sharesOrdinary SharesSEC:0000904454-26-000370:1
4,700 sharesOrdinary SharesSEC:0000904454-26-000370:3
5,295 sharesOrdinary SharesSEC:0000904454-26-000370:0
5,295 sharesOrdinary SharesSEC:0000904454-26-000370:2
1,690 sharesOrdinary SharesSEC:0000904454-26-000370:4
41,671 shares@ US$46.37560.066% mcap13.7% of flowORDINARY SHARESSEC144:0001973379-26-000249
11,685 shares@ US$45.05460.018% mcap62.0% of flowOrdinary SharesSEC144:0001973379-26-000245
25 of 226 declarations
About uniQure N.V.
uniQure N.V. is a gene therapy company listed in the United States on the Nasdaq Global Select Market under the ticker QURE. For French, Belgian and Swiss investors, it fits the profile of a high-risk, high-upside biotechnology name: the company is still largely driven by research and development, regulatory milestones, and clinical readouts, but it also has the potential to generate substantial value if one or more of its lead programs progress successfully.
The company was founded in 1998 through its predecessor, Amsterdam Molecular Therapeutics Holding N.V., and later became uniQure N.V. in connection with its 2014 IPO. Its corporate headquarters are in the Netherlands, while it maintains operations in both Europe and the United States. That transatlantic footprint matters operationally, because gene therapy development requires integrated work across discovery, clinical development, manufacturing, regulatory strategy, and eventual commercialization planning.
Read moreShow less
uniQure’s core business is built around an adeno-associated virus, or AAV, gene therapy platform, supported by proprietary commercial-grade manufacturing capabilities. In practical terms, the company seeks to deliver one-time treatments that could offer durable or potentially curative benefits for severe genetic diseases. This is a specialized niche within biopharma, where scientific differentiation, manufacturing reliability, and regulatory credibility are all critical.
The pipeline is concentrated in a small number of strategic programs, which is typical for an advanced-stage biotech. The most important asset is AMT-130, an investigational gene therapy for Huntington’s disease. uniQure is also developing programs in rare neurological and neuromuscular indications, including SOD1-ALS. This focus gives the company meaningful upside if data are positive, but it also creates concentration risk: any setback in safety, efficacy, or regulatory dialogue can materially affect valuation.
From a competitive standpoint, uniQure operates in a field populated by other gene therapy specialists and larger pharmaceutical companies that have entered the space selectively. Its advantage lies in its long operating history, platform expertise, and experience translating AAV science into clinical programs. At the same time, the company remains dependent on capital markets and collaboration opportunities, and like many development-stage biotech companies it has reported recurring net losses and accumulated deficits.
Recent developments underscore both the promise and the uncertainty of the story. In 2025, uniQure raised equity capital several times to support operations and development activities. Most notably, the company disclosed in late 2025 that the FDA’s final meeting minutes regarding AMT-130 were more cautious than the company had hoped, indicating that Phase I/II data may not be sufficient as primary evidence for a BLA submission. In early 2026, the company continued to provide operational and financial updates, reinforcing that the path to a potential U.S. launch remains a key investment focus. Overall, uniQure is a compelling Nasdaq-listed United States biotech story centered on gene therapy innovation, but one that should be assessed through a strict clinical and regulatory lens.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
